ELVN Enliven Therapeutics
- 27.650
- +0.020+0.07%
- 27.000
- -0.650-2.35%
Enliven Therapeutics News
Enliven Therapeutics Price Target Announced at $36.00/Share by Jones Trading
JonesTrading Initiates Enliven Therapeutics(ELVN.US) With Buy Rating, Announces Target Price $36
Enliven Therapeutics Analyst Ratings
H.C. Wainwright Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $37
Enliven Therapeutics Garners Buy Rating on Robust Clinical Results and Safety Profile for Lead CML Drug Candidate
Mizuho Securities Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $39
TD Cowen Maintains Enliven Therapeutics(ELVN.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Demant (OtherWILLF) and Enliven Therapeutics (ELVN)
LifeSci Capital Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $38
Mizuho Securities Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $39
H.C. Wainwright Initiates Enliven Therapeutics(ELVN.US) With Buy Rating, Announces Target Price $37
HC Wainwright & Co. Initiates Coverage On Enliven Therapeutics With Buy Rating, Announces Price Target of $37
Enliven Therapeutics Analyst Ratings
Analysts' Top Healthcare Picks: Enliven Therapeutics (ELVN), Ascendis Pharma (ASND)
Mizuho Securities Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $39
TD Cowen Maintains Enliven Therapeutics(ELVN.US) With Buy Rating
LifeSci Capital Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $38
Buy Rating for Enliven Therapeutics Backed by Promising Clinical Data and Market Potential
TD Cowen Maintains Enliven Therapeutics(ELVN.US) With Buy Rating
Buy Rating Justified by Enliven Therapeutics' Drug Progress and Strong Financials
Analysis
Price Target
No Data
No Data